At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Acalabrutinib 129 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Arm, Phase II Study of Acalabrutinib as Post-Autologous Blood or Marrow Transplant (BMT) Maintenance Therapy in Subjects With Mantle Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib for Mantle Cell Lymphoma. Completed, enrolled 15 participants across 4 sites.
Detailed Summary
This is a phase II study to evaluate efficacy of Acalabrutinib as a maintenance therapy following blood or marrow transplant (BMT) in patients who have been diagnosed with mantle cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma
CountriesUnited States
CollaboratorsAcerta Pharma, LLC
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartAug 2020
Primary CompletionApr 2024
TodayJul 2026
First PostedMay 26, 2020
Enrollment StartAug 7, 2020
Primary CompletionApr 5, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.1 years ago
Interventions
Acalabrutinibdrug
Acalabrutinib 129 mg will be self-administered orally twice daily (BID) starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.